Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coherus delivered weaker-than-expected revenue and earnings for the third quarter. It also lowered its revenue outlook for the year, blaming delays in its planned commercial launches for Udenyca OnBody and Loqtorzi.

Why Coherus Biosciences Stock Dropped Today

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - President, CEO and Chairman Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Yigal Nochomovitz - Citigroup Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Christopher Schott - JPMorgan Ash Verma - UBS Operator Good day and thank you for standing by.

Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript

– Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI™ now approved with launch planned for the first quarter of 2024 – – Conference call today at 5:00 p.m. Eastern Time –

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

Coherus BioSciences to Participate at Upcoming November Investor Conferences

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for nasopharyngeal carcinoma (NPC). Coherus management has insisted they will "not engage in heavily discounted pricing" for the drug.

Why Coherus BioSciences Stock Soared Today

McDonald's

Coherus BioSciences stock CHRS, -3.65% rose 17% as the Food and Drug Administration approved its treatment for nasopharyngeal cancer when combined with chemotherapy that it makes with Shanghai Junshi Biosciences.

Intuitive Machines stock climbs on lunar mission plan as McDonald's edges higher ahead of results

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemotherapy —

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

Coherus announced it has resubmitted a biologic license application for one of its products. The FDA had previously issued a complete response letter holding up the product's approval, citing an ongoing review at a manufacturing site.

Why Coherus BioSciences Stock Popped Today

– Resubmission follows the satisfactory resolution of the FDA's review of inspection findings at  the third-party filler –

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply addresses market need and expands anti-VEGF options across the retinal market – REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that sales of CIMERLI® (ranibizumab-eqrn) to retinal specialists have exceeded 100,000 doses since commercial launch on October 3, 2022.

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down

Coherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a treatment designed to cut cancer patients' risk of infection after chemotherapy. The rejection was due to ongoing review of inspection findings at a third-party filler and did not identify any issues with Udenyca Onbody's clinical efficacy, safety or device design, the company said.

Coherus BioSciences' new injector treatment for cancer patients rejected by FDA

– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment –

Coherus Completes Surface Oncology Acquisition

It is about to be deleted from a popular small-cap equity index. As of Monday, Sept.

Why Coherus BioSciences Stock Was Plunging This Week

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

Coherus BioSciences to Participate at Upcoming September Investor Conferences

Surface Oncology Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS). Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Co.

SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Marek Ciszewski – Senior Vice President-Investor Relations Denny Lanfear – President, CEO and Chairman Paul Reider – Chief Commercial Officer Theresa LaVallee – Chief Development Officer Rosh Dias – Chief Medical Officer McDavid Stilwell – Chief Financial Officer Conference Call Participants Robyn Karnauskas – Truist Securities Michael Nedelcovych – TD Cowen Douglas Tsao – H.C. Wainwright Chris Schott – JPMorgan Ash Verma – UBS Operator Good day and thank you for standing by.

Coherus BioSciences, Inc. (CHRS) Q2 2023 Earnings Call Transcript

– Net revenue rose 81% from prior quarter to $58.7 million – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July – – Planned merger with Surface Oncology expected to significantly advance next-generation immuno-oncology pipeline – – Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

Pagaya Technologies Ltd

TC Biopharm Holdings PLC

Why would anyone want to buy penny stocks? They're extremely risky.

News for Coherus BioSciences Stock (CHRS)